All Posts

by Vista Partners LLC November 20, 2025

Abbott’s Cancer Diagnostics $21B Gamble: The Exact Sciences Buyout Explained -( $ABT $EXAS $IBB $IYH )

Abbott Laboratories (ABT) is making headlines with its latest $21 billion cash deal to acquire Exact Sciences (EXAS), a move that not only sends ripples through the diagnostics world but also gives Wall Street’s quants and humorists some fresh material for dinner party banter. Forget colonoscopies: the big story now is whether Abbott, having mastered everything from diabetes to infectious disease testing, can pull off its much-anticipated entrance into the $60 billion U.S. cancer screening arena—without tripping over the price tag or institutional egos.

The Corporate Chess Match

In this sector-defining transaction, Abbott is offering Exact Sciences shareholders $105 per share, representing a 22–51% premium and enough zeros to make any biotech C-suite wish they’d developed a colorectal test as catchy as Cologuard. While Exact’s Madison, Wisconsin headquarters will remain intact (no cheese plate disruption here), CEO Kevin Conroy will transition to an advisory role—presumably to ensure that Abbott learns how to spell “Oncotype DX” correctly at board meetings.

Diagnosing Growth: Financials and Foresight

Abbott is absorbing Exact’s estimated $1.8 billion in net debt, while betting the farm on the planned 2026 closing date and regulatory blessings just shy of sainthood. Exact is expected to deliver $3 billion in revenue this year, with growth rates in the high teens; this will push Abbott’s total diagnostics revenue to an impressive $12 billion annually once the ink dries—an expansion that should help paper over those post-pandemic COVID test sales doldrums.

Strategic Humor and Market Satire

As industry analysts point out, Abbott didn’t just buy a box of lab results—they acquired the entire narrative franchise. TD Cowen dubs this deal a “revitalization,” while Leerink calls it “sector-defining.” Wall Street wits, meanwhile, are abuzz: Was the real due diligence performed via a Cologuard kit after a particularly acrimonious earnings call? Does Abbott’s pivot from sniffing out viruses to screening for more elusive cellular mischief signal a new era for consumer diagnostics, or just retail therapy on a grand scale?

Sector Implications: A New Growth Engine

Abbott’s deal is poised to transform the company’s growth pathway, bringing advanced noninvasive screening tests and precision oncology diagnostics to the fore. Not only does this acquisition shore up Abbott’s diagnostics vertical, but it also validates the rapidly evolving central lab business model—and perhaps gives new meaning to the phrase “healthcare consolidation,” minus any digestive discomfort.

The Sum…

Abbott’s multi-billion-dollar bet on Exact Sciences shows that humor and innovation both pay dividends—so long as you’ve got the market-leading test, a hefty bank balance, and a CEO who knows how to let go gracefully. Investors, take note: It’s not every day that colorectal cancer screening becomes the punchline and the windfall—at least not in Madison.

The Sources

by Vista Partners LLC November 20, 2025

Walmart’s $179B Quarter: E-Commerce Boom & New Nasdaq Ambitions -( $WMT $DIA $SPY )

Walmart’s (WMT) latest earnings report is a masterclass in retail resilience, with the Bentonville behemoth posting a 5.8% year-over-year revenue jump to $179.5 billion for Q3 2025—exceeding Wall Street’s expectations by a healthy margin. The numbers tell a story of disciplined execution: same-store sales rose 4.5%, e-commerce surged by 28%, and the retailer’s global advertising arm saw a 53% spike in revenue, fueled by its Walmart Connect retail media business. As the holiday shopping season looms, Walmart is not just surviving inflation and cautious consumers—it’s thriving, thanks to a relentless focus on affordability, operational efficiency, and a tech-forward strategy that’s redefining the retail landscape.

A Retail Giant’s Holiday Playbook

Walmart’s latest quarter was driven by a surge in both transactions and average ticket size, with shoppers increasingly drawn to its value proposition amid a more price-sensitive environment. The retailer’s U.S. grocery segment remains a powerhouse, accounting for about half of its roughly 7,400 temporary price reductions—proof that Walmart is still the go-to for bargain hunters and budget-conscious families. Meanwhile, international sales climbed 10.8%, led by strong performances in India and China, further diversifying Walmart’s global footprint.

E-Commerce: The New Engine of Growth

If there’s a hero in Walmart’s earnings narrative, it’s e-commerce. Online sales jumped 28%, marking the seventh consecutive quarter of double-digit growth in the segment. The retailer’s store-based delivery network played a starring role, with one-third of recent deliveries arriving in under three hours and 20% in less than 30 minutes. This speed, combined with a growing marketplace and third-party seller ecosystem, has cemented Walmart’s position as a tech-savvy competitor to Amazon.

Wall Street’s Holiday Cheer

Analysts have responded with optimism, raising Walmart’s full-year net sales forecast to between 4.8% and 5.1%—a move that reflects confidence in the retailer’s ability to maintain momentum even as other big-box chains scale back expectations. Adjusted EPS reached $0.62, two cents above consensus, while net income surged 33% year-over-year to $6.14 billion. Walmart’s operating margin held steady at 3.7%, a testament to its ability to manage costs while driving growth.

The Nasdaq Gambit

In a move that signals Walmart’s ambition to be seen as a technology leader, the company announced plans to shift its stock listing from the New York Stock Exchange to Nasdaq in December. This symbolic gesture underscores Walmart’s transformation from a traditional retailer to a digital powerhouse, leveraging AI, retail media, and omnichannel fulfillment to capture market share across income groups.

The Takeaway

Walmart’s Q3 performance is a reminder that in retail, size and scale still matter—but so does innovation. As competitors grapple with economic headwinds, Walmart is not just weathering the storm; it’s setting the pace, offering shoppers value, speed, and choice, all while positioning itself for a tech-driven future. The message to Wall Street is clear: when it comes to retail, Walmart is still playing offense, and the holidays may be just the beginning.

The Sources…

by Vista Partners LLC November 20, 2025

Three Mile Island Returns: Why Nuclear Energy Is Back in the S&P 500 Spotlight -( $CEG $OKLO $MSFT $SPY )

Constellation Energy (CEG $357.48, +59.80% YTD), the $40 billion titan of electrons whose stock has been radiating in the S&P 500 like a newly uncorked isotope, just pocketed a $1 billion federal loan courtesy of the Trump administration’s Energy Dominance Financing program. The catch? Restarting the legendary Three Mile Island nuclear reactor—yes, the same site whose cooling towers are as culturally embedded in Pennsylvania as cheesesteak and, once upon a time, existential dread.

S&P 500’s Nuclear Glow

Of course, Wall Street noticed. Constellation shares popped faster than a particle in a proton accelerator—mirroring the VanEck Uranium and Nuclear ETF’s uranium-fueled 55% run in 2025, leaving the S&P 500’s 14% gain in the rear-view mirror with all the dignity of a short-seller in a bull market. Tech behemoths like Microsoft (MSFT) have waded in too, eyeing the revived 835-megawatt reactor to power AI data centers—a dazzling marriage of digital ambition and radioactive resolve.

Three Mile Island Reimagined

The Three Mile Island site (now rebranded as the Crane Clean Energy Center, because who says nuclear PR can’t have a little panache?) closed in 2019, but never quite faded from the grid or the collective memory. Now, it’s getting the ultimate stimulus package—energy for the grid, jobs for the Mid-Atlantic, and a little piece of regulatory performance art as Constellation guarantees the project’s success, or the taxpayer walks away none the poorer.

Enter Oklo: The DARPA of Nuclear?

While Constellation is busy spiffing up yesterday’s infrastructure, Oklo Inc. (OKLO, $102.86, +384.50% YTD) is scripting nuclear’s next act with the flair of a Silicon Valley disruptor who’s seen too many Bond movies. Oklo’s Aurora powerhouse, a sodium-cooled fast reactor designed to run on recycled nuclear fuel, is already laying its foundations at Idaho National Laboratory—complete with a new Siemens Energy turbo-generator contract signed this week, for those who like their power blocks delivered with German precision and American optimism.

Data Centers and the Aurora Order Book

Oklo’s ambitions match Constellation’s wattage, but with some subtle startup swagger. The company has inked nonbinding agreements for about 4,750 MW of supply—with data center heavyweights like Equinix and Switch prowling its order book, pushing the pipeline close to 18 gigawatts. Think 21st-century oil rush—except the prospector wears a lab coat and talks about “HALEU” instead of high-octane gasoline.

The Nuclear Renaissance: High Stakes, High Humor

Call it a nuclear renaissance, or call it Fission: The Musical. The Energy Department says the Three Mile Island reboot will cut energy costs, create over 600 jobs, and help win the AI arms race—a tall order, but not as ambitious as Oklo’s bid to recycle spent nuclear fuel and peddle it to data centers desperate for a carbon-light edge.

Constellation gets the glory of reviving a legend, Oklo gets the thrill of building a new one, and somewhere on Wall Street, analysts run the numbers, compare megawatts to mouse clicks, and quietly wonder when uranium stocks will be traded like Taylor Swift concert tickets.

Nuclear is back, whether you’re nostalgic for the past or betting on the next big thing. Just don’t call it a comeback—the atoms have always been here, waiting for another spin on the grid.

The Sources…

by Vista Partners LLC November 19, 2025

Insulet’s Growth Spurt Meets Modular’s Regulatory Push -( $PODD $MODD $ABT $DXCM )

Insulet’s (PODD) latest run of press releases reads like a victory lap for a company that has turned tubeless insulin delivery into a global franchise, while Modular Medical (MODD) is quietly trying to crash or expand the same party with a stripped‑down, value‑oriented, easier to use Pivot Patch Pump now stepping into the regulatory spotlight. In diabetes tech terms, Insulet is hosting the conference and Modular is slipping in through the side door with an IRB badge and a 510(k) file folder.

Insulet: podium position in patch pumps

Over its last three communications, Insulet has sketched a familiar but enviable picture: Omnipod 5 driving double‑digit top‑line growth, a widening global footprint, and enough investor confidence to justify a dedicated Investor Day at headquarters. Third‑quarter results showed Omnipod sales climbing roughly 30% year over year to just under $700 million, prompting yet another bump to full‑year revenue guidance and reinforcing Insulet’s status as the category’s scale incumbent.

Strategically, management is signaling that this is not just a pump company, but a consumer‑health platform wrapped around a pod, with expansion into new geographies and additional non‑insulin indications part of the longer‑term roadmap. The upcoming Investor Day is billed as a showcase for that evolution—part factory tour, part strategy seminar, and part reminder that Insulet’s moat is measured in installed base, data, and distribution, not just plastic and electronics.

Omnipod 5: the high‑end benchmark

Operationally, Omnipod 5 remains the product to beat, combining automated insulin delivery with tight CGM integration and a fully tubeless, wearable format that Insulet continues to roll out across North America and Europe. In markets like the U.K., Netherlands, and Canada, the system now pairs with both Dexcom (DXCM) and Abbott (ABT) sensors, giving prescribers and patients the rare luxury of choice in a segment where hardware ecosystems typically demand monogamy.

That combination of algorithmic automation, broad age indications, and smartphone control helps explain why analysts remain comfortable underwriting 20‑plus percent growth off an already large base. It also sets the competitive bar: any challenger patch pump must either offer a meaningfully better experience or a meaningfully lower cost—ideally both—just to get a hearing from payers and clinicians already invested in the Omnipod infrastructure.

Modular’s Pivot: the budget disruptor

Enter Modular Medical’s (MODD) Pivot tubeless patch pump, which has now cleared two key milestones in less than a week: FDA 510(k) submission and Institutional Review Board approval for an in‑house insulin delivery study using the commercial‑form device. The company is explicitly aiming at what it calls the “almost‑pumper” segment (~$3B opportunity)—insulin users who have balked at legacy systems on complexity or cost—by promising a simpler, more affordable patch pump with a removable three‑milliliter reservoir and a two‑part, detachable design.

The near‑term plan is straightforward: gather real‑world usability and performance data under IRB oversight while the FDA digests the 510(k), and prepare manufacturing so that, in a best‑case scenario, commercial launch could follow in early 2026. Importantly, the company is careful to note that Pivot is not yet cleared for sale, underscoring that execution risk still sits squarely with regulators and the company’s ability to scale production and convert those “almost‑pumpers” into paying customers.

Two patch pumps, one crowded lane

From a market‑structure perspective, Insulet and Modular are nominally in the same business—tubeless insulin delivery—but increasingly targeting different corners of the runway. Insulet is optimizing a premium, feature‑rich ecosystem that leans into CGM partnerships, software updates, and international expansion; Modular is positioning Pivot as the minimalist alternative for patients who just want reliable basal and bolus delivery without a graduate degree in diabetes tech.

If Insulet wins by deepening engagement with existing pump users and expanding globally, Modular’s opportunity lies in expanding the total patch‑pump pie by converting injections to pumps in a cost‑conscious cohort that has historically been under‑served. Whether that turns into a complementary dynamic or a competitive collision will depend on how aggressively payers push for lower‑priced options once Pivot is, if ever, on the formulary menu.

Investor angle: incumbents vs insurgents

For investors, the setup resembles a familiar medtech narrative: a scaled incumbent delivering clean beats, margin expansion, and a well‑telegraphed capital‑allocation framework, while a micro‑cap insurgent courts attention with regulatory catalysts and promises of a cheaper mousetrap. Insulet’s near‑term story hinges on sustaining mid‑20s revenue growth and translating Omnipod scale into operating leverage, themes likely to be front and center at the November 20 Investor Day.

Modular Medical (MODD), by contrast, is still in the proving‑ground phase where each press release—an FDA submission here, an IRB approval there—serves as both scientific milestone and investor‑relations oxygen. In a market where tubeless pumps have already gone mainstream, Pivot doesn’t need to dethrone Omnipod so much as demonstrate that there is room, and reimbursement, for a second act in patch‑pump innovation—this time aimed squarely at those who have been almost, but not quite, ready to take the plunge.

The Sources..

by Vista Partners LLC November 19, 2025

Nvidia’s Blockbuster AI Beat Lifts Wall Street: Stock Market Recap – November 19, 2025 -( $AAPL $EXAS $GOOG $NVDA $OKLO $SER $TSLA $TSM $VIX Rise!)

U.S. stocks closed Wednesday looking more contemplative than chaotic, as Wall Street tiptoed into the bell ahead of Nvidia’s after-hours earnings—and then promptly exhaled when the AI titan delivered another blockbuster beat. The S&P 500 and Nasdaq finished modestly higher after shaking off early jitters, the Dow lagged as old‑economy names took the brunt of profit‑taking, and small caps quietly outperformed through the Russell 2000, suggesting that not every trader is hiding exclusively in megacap AI royalty.barrons+3

Indices and macro backdrop

By the close, the S&P 500 settled around 6,642.16, up slightly by .38% on the day and clinging to its reputation as the market’s emotional barometer, while the Nasdaq Composite edged .59% higher to 22,564.23 as traders leaned back into chips and software ahead of Nvidia’s print. The Dow finished in the just in the green up .10% at 46,138.77, whereas the Russell 2000 failed to eke out a gain moving .04% lower to 2,347.89 as bargain hunters sifted among beaten‑up small caps for anything resembling mispriced growth.

The economic calendar remained distorted by the after‑effects of this year’s federal shutdown, with some key releases still shuffled further out on the schedule and investors relying more heavily on high‑frequency indicators and corporate guidance than on a clean run of government data. FOMC‑wise, there was no rate decision on today’s docket, but the market’s attention stayed locked on the coming minutes and the next meeting window, with futures pricing hold at the next meeting and a slower, gentler path to cuts than traders had hoped for a month ago.

Rates, curve, tariffs and DC

Treasury yields drifted higher again, pushing the 10‑year toward the upper end of its recent range at 4.142% and the 2‑year at 3.604%.. The move reinforced the “higher for longer” narrative: enough to unsettle richly valued growth shares intraday, but not so violent as to trigger outright capitulation across equities.

Tariff talk and trade maneuvering stayed in the background, with the administration still exploring targeted tweaks that would ease costs on some consumer imports while keeping broader leverage in place, a compromise that markets greeted with something between a shrug and a polite nod. The shutdown saga, for now, is filed under “temporarily resolved but not forgotten,” as rate‑sensitive sectors continue to trade as if budget brinkmanship could return on short notice.

Nvidia and the tech complex

The evening’s main act belonged unmistakably to Nvidia (NVDA, $186.52, +2.85%), which reported another crushing quarter after the close, with revenue and earnings both topping already‑lofty expectations and data‑center demand once again doing the heavy lifting. Management highlighted ferocious appetite for its Blackwell‑generation AI chips—described as “off the charts”—and guided in a way that reassured investors that fears of an imminent AI hardware bust remain premature. Nvidia reported record revenue for the third quarter ended October 26, 2025, of $57.0 billion, up 22% from the previous quarter and up 62% from a year ago. For the quarter, GAAP and non-GAAP gross margins were 73.4% and 73.6%, respectively. For the quarter, GAAP and non-GAAP earnings per diluted share were both $1.30.

Nvidia shares, which had already firmed into the close, jumped sharply in after‑hours trading to the $193.87 range as options desks scrambled to re‑hedge, and the broader chip complex caught a sympathetic bid in extended hours as well. That late surge set the stage for tomorrow’s open, with traders now debating whether a near‑perfect quarter in the market’s AI bellwether is enough to reset the tone for the entire tech sector—or whether it merely raises the bar for everyone else. During the first nine months of fiscal 2026, NVIDIA returned $37.0 billion to shareholders in the form of shares repurchased and cash dividends. As of the end of the third quarter, the company had $62.2 billion remaining under its share repurchase authorization. NVIDIA will pay its next quarterly cash dividend of $0.01 per share on December 26, 2025, to all shareholders of record on December 4, 2025.

Individual movers

Eli Lilly (LLY, $1049.60, +1.90%) spent the session largely in the role of high‑quality bystander, trading sideways to modestly higher as investors continued to view its weight‑loss and diabetes franchises as long‑duration cash‑flow machines rather than sources of short‑term drama. Taiwan Semiconductor’s (TSM, $282.37, +1.60%) U.S. listing tracked the chip tape, firming into the close as investors leaned into the broader AI‑foundry narrative that keeps it at the center of nearly every advanced‑node capacity conversation.

Alphabet (GOOG) was again strong closing at $292.99, +2.82%. Apple (AAPL, $268.56, +.42%) saw a similar, if milder, pattern as investors weighed its new four‑trillion‑dollar‑club status against the uncomfortable arithmetic of slower device growth and a higher discount rate.

Tesla (TSLA) traded .68% higher to $403.99 amid a broader cooling in high‑beta growth and ongoing questions about EV demand, margins and corporate drama, while Meta (META, $590.32, -1.23%) drifted in sympathy with other ad‑ and engagement‑driven names. Broadcom, Oracle and Intel were mixed on the day—each still fundamentally lashed to the AI and data‑center story, but now trading stock‑by‑stock as investors differentiate between pure‑play accelerators, networking, and legacy CPU and enterprise software exposure.

Palantir (PLTR) once again acted like a levered sidecar on AI sentiment, finishing lower by 1.14% to $165.42 after a volatile session as money rotated toward names perceived as software beneficiaries of the same infrastructure wave Nvidia is powering in hardware. At the more speculative end of the tape, Opendoor (OPEN, $6.69,-11.04%) shares fell by double digits and nuclear‑upstart Oklo (OKLO) traded 6.45% higher to $102.86 as Oklo and Siemens Energy announced that they have signed a binding contract for the design and delivery of the power conversion system for Oklo’s Aurora powerhouse. The agreement authorizes Siemens Energy to begin engineering and design work to expedite procurement of long-lead components and initiate the manufacturing process for the power conversion system. This partnership on key components combines Oklo’s expertise in advanced fission technology with Siemens Energy’s industry-leading steam turbine and generator systems to deliver clean, reliable electricity using proven industrial equipment.

Deals, IPOs, commodities and crypto

The primary market stayed relatively subdued, with no headline‑grabbing mega‑mergers or splashy NYSE/Nasdaq IPOs to rival the AI earnings spectacle, as prospective issuers continued to wait for a cleaner read on volatility and the Fed’s trajectory. Deal chatter persisted in the background across media, telecom and energy, but nothing crossed the tape that changed the broader equity narrative for the day.

In commodities, crude oil fell to $59.42, -2.06% as traders reassessed supply risks and demand resilience. Gold at $4,078.40 and silver at $51.04 remained choppy, caught between higher real yields and lingering geopolitical and macro anxiety, leaving each to serve simultaneously as inflation hedge, recession hedge and sometimes‑disappointing portfolio decoration.

Bitcoin hovered near the psychologically important 90,000 area after recently breaking below prior support, its slide emblematic of how tightly crypto has become correlated with high‑beta tech in a world where rate‑cut hopes keep getting pushed out. For now, the message from today’s tape is clear: the market will tolerate higher yields and macro uncertainty—so long as the AI profit engine, led by Nvidia, continues to deliver numbers that justify the fever dream.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.4909), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, today (Nov. 17) announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion. On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.20), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated, “These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.4148, +1.67%), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, reported (Nov. 13) its financial results for the quarter ended September 30, 2025, and provided a business update highlighting key corporate and clinical advancements across its vaccine and oncology programs. David Dodd, CEO of Geovax stated, “As highlighted in this report, during the third quarter GeoVax continued making important progress, advancing innovative vaccines and immunotherapies that address urgent and underserved medical needs. With continued global Mpox spread and constrained vaccine supply, our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform. Our EMA and BARDA-aligned program position GeoVax to accelerate regulatory readiness and commercial entry. For our GEO-CM04S1 COVID-19 vaccine program, recent clinical presentations validate our belief that multi-antigen vaccines – expressing both spike and nucleocapsid – are essential for breadth and durability in vulnerable immunocompromised populations. In particular, the robust immune responses demonstrated in Chronic Lymphocytic Leukemia (CLL) patients represents a meaningful step forward in addressing the unmet needs of over 40 million immunocompromised Americans. In our Gedeptin(R) oncology program, the expansion into multiple solid tumor indications builds upon a growing recognition that tumor-targeted immune priming can dramatically improve checkpoint outcomes. We are executing a clear path to clinical and commercial value creation. GeoVax continues to execute with purpose and discipline. Our multi-antigen vaccine and immunotherapy platforms position the Company squarely within the national call to strengthen America’s health security, expand domestic manufacturing, and deliver equitable global solutions.”

Volato Group, Inc. (NYSE American: SOAR, $1.12) and M2i Global, Inc. (MTWO, $.0998) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $3.8640, +2.77%) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s diseas. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $33.31) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

Exact Sciences Corp. (NASDAQ: EXAS, $86.18, +23.68%), a leading provider of cancer screening and diagnostic tests, announced (Nov. 7) pivotal clinical validation results from the ALTUS study (NCT: 05064553). The prospective, head-to-head trial demonstrated that the company’s Oncoguard® Liver blood test delivers superior early-stage and overall sensitivity for hepatocellular carcinoma (HCC) — the most common form of liver cancer — compared to the current standard of care.

Nokia (NOK) is promising investors a sleeker, AI‑age version of itself by 2028, aiming to lift profits by as much as 60% while quietly admitting that the road there runs through a restructuring zone. The market, in classic fashion, responded to this vision of future riches by sending the stock currently lower on the day, but is currently up +45.54% over the last year at $6.04

The Sources

https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/35843242/5-top-artificial-intelligence-ai-stocks-to-buy-in-november/

https://www.barrons.com/livecoverage/stock-market-news-today-111925

https://www.barrons.com/livecoverage/stock-market-news-today-111925/card/s-p-500-kicks-higher-at-finish-now-its-nvidia-time–pm0tSVrhW1v1Do5z8HMy?mod=bar_FV

https://www.marketwatch.com/livecoverage/stock-market-today-dow-sp500-nasdaq-steady-after-4-day-losing-streak-nvidia-earnings/card/s-p-500-futures-show-sell-off-stalled-as-traders-eye-nvidia-results-2WGvK0bxH6LrBygDrEZw

https://finance.yahoo.com/quote/%5EGSPC/history/

https://www.thestreet.com/latest-news/stock-market-today-nasdaq-sp-500-futures-turn-to-upside-as-nvidia-earnings-loom

https://us.plus500.com/newsandmarketinsights/global-stocks-fall-tech-bitcoin-oil-november-2025

https://www.bls.gov/bls/2025-lapse-revised-release-dates.htm

https://tradingeconomics.com/united-states/calendar

https://www.census.gov/economic-indicators/calendar-listview.html

https://www.marketwatch.com/economy-politics/calendar

https://www.newyorkfed.org/research/calendars/nationalecon_cal

https://www.bea.gov

https://www.wsj.com/livecoverage/nvidia-earnings-stock-market-today-11-19-2025

https://www.globenewswire.com/news-release/2025/11/19/3191444/0/en/NVIDIA-Announces-Financial-Results-for-Third-Quarter-Fiscal-2026.html

https://finance.yahoo.com/news/nvidia-announces-financial-results-third-212000333.html

https://www.tipranks.com/news/nvda-earnings-nvidia-q3-revenues-surpass-50b-beats-earnings-estimates

https://uk.finance.yahoo.com/news/earnings-live-nvidia-q3-results-beat-ceo-jensen-huang-says-blackwell-chip-demand-is-off-the-charts-213245875.html

https://www.businessinsider.com/nvidia-q3-earnings-live-updates-nvda-stock-price-ai-chips-2025-11

https://www.investopedia.com/nvidia-earnings-live-coverage-q3-fy2026-11852941

https://www.cnbc.com/2025/11/19/nvidia-reports-third-quarter-results-after-the-bell-heres-what-wall-street-expects-.html

https://finance.yahoo.com/news/stock-market-news-nov-19-143100915.html

https://www.youtube.com/watch?v=TH707KA8CGs

https://swingtradebot.com/news-articles/22267452-dow-jones-hits-record-close-palantir

https://x.com/stats_feed/status/1983188044019630372

https://www.governance-intelligence.com/shareholders-activism/week-grc-tesla-sets-november-date-2025-agm-amid-corporate-turmoil

https://polymarket.com/event/pltr-up-or-down-on-november-19-2025/pltr-up-or-down-on-november-19-2025

https://stockanalysis.com/stocks/pltr/history/

https://www.eoption.com/morning-preview-november-19-2025/

https://www.economies.com/crypto/analysis/evening-update-for-bitcoin-(btcusd)–19-11-2025-122806

https://www.investing.com/analysis/bitcoin-weakness-echoes-through-gold-as-traders-react-to-fed-signals-200670418

https://economictimes.com/news/international/us/bitcoin-ether-and-solana-all-crashing-hard-as-more-than-1-trillion-lost-why-crypto-prices-are-falling-so-sharply-and-how-long-could-this-crypto-correction-last/articleshow/125444030.cms

https://www.reuters.com/business/us-stock-futures-slip-rate-cut-hopes-fade-valuation-worries-persist-2025-11-18/

https://www.morningstar.com/news/marketwatch/20251118110/the-sp-500-and-dow-extend-their-losing-streaks-to-a-fourth-day-are-stocks-headed-for-a-full-10-correction

https://www.cnbc.com/2025/11/17/stock-market-today-live-updates.html

https://www.bloomberg.com/news/articles/2025-11-18/stock-market-today-dow-s-p-live-updates

https://finance.yahoo.com/news/november-technology-portfolio-launches-insights-110000020.html

https://www.home.saxo/content/articles/macro/market-quick-take—19-november-2025-19112025

by Vista Partners LLC November 19, 2025

Nokia Targets 60% Profit Lift by 2028 as It Rolls Out AI‑Ready Networks -( $NOK $NVDA $SPY )

Nokia (NOK) is promising investors a sleeker, AI‑age version of itself by 2028, aiming to lift profits by as much as 60% while quietly admitting that the road there runs through a restructuring zone. The market, in classic fashion, responded to this vision of future riches by sending the stock currently lower on the day, but is currently up +45.54% over the last year at $6.04.

Big profit promises, modest patience

By 2028, Nokia wants to grow its comparable operating profit to a range of roughly €2.7 billion to €3.2 billion, up from about €2.0 billion over the last 12 months—a target that sounds ambitious until one remembers how many network cycles the company has already lived through. The goal implies a potential profit boost of up to about 60%, built on higher-margin network gear and tighter cost control rather than a sudden global love affair with telecom capex.

Two segments, one makeover

To get there, Nokia is stripping its structure down to two primary operating segments—Network Infrastructure and Mobile Infrastructure—starting in 2026, a move executives say will sharpen focus and speed decisions as AI and data centers soak up ever more bandwidth. Several smaller units, from fixed wireless CPE to microwave radio, are being shunted into “portfolio businesses” pending strategic decisions, corporate code for “for sale, to be partnered, or put on a strict performance diet.”

Chasing the AI supercycle

The official strategy now revolves around the “AI supercycle,” with Nokia pledging to accelerate growth in AI and cloud, lead the next era of mobile connectivity with AI‑native networks and 6G, and co‑innovate with customers who increasingly look more like hyperscalers than legacy phone companies. Network Infrastructure is expected to grow net sales at a 6–8% annual clip from 2025 to 2028, with optical and IP networks targeted for a double‑digit growth rate as data centers demand fatter, faster pipes.

Margins, KPIs and a skeptical Street

On the numbers, Nokia is aiming for a 13–17% operating margin in Network Infrastructure and a 48–50% gross margin in Mobile Infrastructure by 2028, while cutting group “common and other” operating expenses to €150 million from about €350 million. Analysts, however, have already flagged the 2028 targets as underwhelming, a reminder that investors have grown used to confident long‑term plans from gear makers and slightly less confident delivery, particularly when mobile networks are still digesting prior 5G splurges.

From networks to narrative

For now, Nokia’s story is that of a once‑ubiquitous consumer brand recasting itself—again—as the quiet plumbing behind AI‑driven connectivity, hoping investors will pay more for pipes if they are branded “AI‑ready.” Whether the new structure and targets mark the beginning of an AI‑era rerating or just another chapter in Nokia’s long history of reinvention will depend less on slideware and more on whether, by 2028, those promised margins look like engineering reality rather than marketing copy.

By the way, note that Nvidia (NVDA) has made a $1 billion equity investment that secured a 2.9% stake in Nokia….

The Sources…

by Vista Partners LLC November 18, 2025

Recycling as a Resource: Inside EverMetal’s Bid to Turn Trash Into Treasure -( $MTWO $SOAR )

For decades, recycling was the domain of earnest suburban homeowners and aluminum can loyalists. But now, amid geopolitical scrambles for lithium, nickel, and cobalt, the practice has graduated from hobby to high finance. In the latest episode of The Minerals Metals Initiative, Hugo Schumann—CEO and founder of EverMetal Capital—lays out a vision where old circuit boards and discarded batteries become the building blocks of America’s next industrial boom.

A Clean Loop

Schumann, who also leads Elemental Group USA and manages nearly 50 recycling sites nationwide, describes his company’s goal with the crisp confidence of a fund manager discussing an overlooked asset class. EverMetal styles itself as the world’s first private equity–backed critical metals recycling platform—a title that sounds equal parts MBA dream and sustainability manifesto. The mission: turn the messy business of scrap into a clean loop for the digital age. The same rare metals pulled from remote mines could one day return through collection networks, ready for a second life in electric vehicles, smartphones, and wind turbines.

Practical & Urgent

It’s a vision that feels both practical and urgent. As the U.S. rushes to secure supply chains for critical materials—many of which are sourced from geopolitically delicate corners of the world—the ability to reclaim metals domestically has become less an environmental ideal and more an economic necessity. But to do that, Schumann insists, the nation needs two balancing forces: better collection systems and smarter consumer incentives. Without them, far too many obsolete gadgets will remain in closets instead of rejoining the mineral supply chain.

The Sum..

The episode, titled “Recycling as a Resource: Critical Metals Recycling and the Circular Economy,” runs like a master class in modern material strategy. It’s also refreshingly pragmatic, stripping sustainability of its buzzwords and treating it instead as shrewd resource management—a discipline Wall Street might finally take seriously.

USA flag with 'Critical-Minerals' enclosed in a circle overlay.

Further Afield: Volato and M2i Global Advance Development of Strategic Mineral Reserve Digital Infrastructure

Volato Group, Inc. (NYSE American: SOAR) (“Volato”) and M2i Global, Inc. (OTCQB: MTWO) (“M2i”) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations.

This infrastructure is being developed to serve as the market-facing layer of the U.S. Critical Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Unlike securities or commodities exchanges, this system focuses exclusively on physical materials. It enables direct contracting, leasing, collateralization, and trust-held arrangements between qualified participants, without trading or listing securities, futures, or derivatives—ensuring clear compliance with U.S. and allied regulatory frameworks.

Building on Volato’s expertise in scalable aviation software and real-time asset tracking, Volato and M2i are beginning development of the core transaction and data-integrity systems. M2i continues to lead policy alignment and participant onboarding, while Volato engineers the secure digital infrastructure. By combining Volato’s proven enterprise systems with M2i’s CAINO (Critical Asset Intelligence and Network Operations) compliance stack, the unified team will deliver a secure framework for data exchange, verification, and auditable material movement—creating transparent chains of custody from mine to manufacturer.

“This project represents the convergence of M2i’s critical-minerals strategy and Volato’s track record in building auditable, high-value operational systems,” said Matt Liotta, Co-Founder and CEO of Volato. “Our team is now turning M2i’s blueprint into a working platform that brings transparency and accountability to one of the world’s most strategic supply chains.”

“With Volato leading software development, this effort moves from concept to construction,” said Major General (Ret.) Alberto Rosende, CEO of M2i Global. “This collaboration combines industrial vision with execution capability.”

By combining Volato’s digital infrastructure with M2i’s strategic and operational framework, this initiative addresses one of today’s most pressing industrial challenges: establishing a reliable, transparent supply of materials essential to defense, energy, and technology manufacturing.

This development effort follows the previously announced definitive business combination between Volato and M2i Global, under which Volato will acquire 100% of M2i’s outstanding equity in an all-stock transaction. Upon closing, M2i shareholders are expected to own approximately 85% of the combined company and Volato shareholders approximately 15%. The Boards of both companies have approved the transaction, which remains subject to regulatory review and shareholder approval.

by Vista Partners LLC November 18, 2025

Wall Street Shuffled Its Fearful Feet As Volatility Popped On Tuesday, Nov. 18, 2025 -( $JAZZ $MTWO $ONDS $SOAR $SRRK $VIX Rise!)

Wall Street shuffled its fearful feet on Tuesday, November 18, 2025, as investors digested a buffet of macroeconomic reports, corporate news, and political drama—the kind of day that makes even seasoned traders wish for a stronger coffee and perhaps, a bar of gold for comfort.

Index Highlights

The equities dancefloor looked subdued, with the S&P 500 slipping 0.83% to 6,617.32 and the Dow Jones losing 1.07% to close at 46,091.74—likely tripping over its own blue chips also greeting over Nvidia’s (NVDA) earnings report that is on deck for tomorrow. The tech-heavy Nasdaq composite also dropped 1.21% to 22,432.85, however the Russell 2000 small-cap index actually bounced up .31% to 2,348.74 after the recent risk-off-sell off. Volatility and fear rose again as the makers’s fear gage The VOX closed at $24.69, +10.32% today and is now up a whopping +42.88% over the lat 5-days.

Macroeconomic Reports

Tuesday brought a medley of U.S. economic tea leaves: ADP’s weekly employment change, import/export price stats for October, industrial production figures, and the NAHB Housing Market Index for November—all dropped like breadcrumbs for those watching the Fed’s next move. Decelerating hiring and less-than-robust output kept Wall Street on its toes, with flash PMI data for November anticipated Friday.

Policy & Political Drama

Tariffs: The Trump administration issued a modest reprieve on tariffs for select agricultural goodies such as bananas and tea, possibly inviting traders to toast with a fruity cocktail for once.
US Shutdown: The government shutdown—after a historic, marathon stretch—ended six days earlier, easing pressure on markets. Funding gaps are now the stuff of postmortem analysis and bipartisan grumbling.

Rates, Yield Curve, and Inflation

The Federal Reserve kept investors guessing. While the FOMC has held rates steady, division among its policy-makers grew palpable about whether to snip rates at December’s meeting. The yield curve stayed stubbornly inverted—the 10-year Treasury note yielding 4.12% versus 3.58% for the two-year, driving bond aficionados to recalibrate their risk premia.

A Few Corporate updates

Ondas Holdings (ONDS, $6.84, +166.80% YTD) has officially closed the $225 million deal to acquire Sentrycs, the Israeli cyber-wrangler with a knack for taking over rogue drones—no jamming, no spoofing, just pure protocol manipulation, much to the dismay of any quadcopter plotting against a G20 summit. In a move that’s part chess, part high-tech whack-a-mole, Ondas’ Autonomous Systems unit now absorbs Sentrycs’ vaunted Cyber-over-RF takeover platform, which boasts around 200 real-world deployments across 25 countries, from urban power grids to border outposts.

Anthropic, the AI shop best known for giving ChatGPT’s Claude a run for its money, has announced a jaw-dropping, spreadsheet-busting $30 billion commitment to Microsoft’s Azure cloud platform—a sum large enough to make even the most seasoned CFO reach for a calculator and a calming cup of chamomile tea. The deal, revealed Tuesday, places Anthropic squarely in the ringside seats of the generative AI arms race, and brings with it a rotating cast of tech titans and supersized investment numbers worthy of a Silicon Valley fever dream.

Blue Origin’s CEO, Dave Limp, has sparked industry attention with his stunningly candid forecast: the world’s biggest AI-optimized data centers will soon decamp from the plains of Utah and the forests of Oregon for the final, distinctly real frontier—outer space. Driven by the crushing energy appetite of artificial intelligence, Limp predicts a future where data centers are launched into Earth orbit, free from terrestrial real estate drama and the ever-present threat of squirrels gnawing on fiber optics.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ, $180.52, +6.13%) today announced that the Company will participate in Citi’s 2025 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 2, 2025.

Scholar Rock (NASDAQ: SRRK, $39.81, +9.14%), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: Citi 2025 Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 1:00 p.m. ET on Wednesday, December 3, 2025 in Miami, FL & th 8th Annual Evercore Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 8:20 a.m. ET on Thursday, December 4, 2025 in Miami, FL.

Commodities & Crypto

Gold closed at $4,066/oz, while silver closed at $50.535/oz. Oil rose to $60.587/oz up 1.30% today. Bitcoin—ever the digital outlaw—waltzed through the day with its usual volatility and edged up .89% to $92,790 at the time of this writing today.

Today’s Market in One Line

Stocks faltered as economic clouds lingered, corporate headlines blurred, and politicians put their piñatas away—at least until the next shutdown. And as always, investors wait for the Fed’s next act, hoping it comes with both rate relief and a punchline worthy of a WSJ newsroom.

VP Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.5086), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, today (Nov. 17) announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion. On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $6.37), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated, “These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.4080), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, reported (Nov. 13) its financial results for the quarter ended September 30, 2025, and provided a business update highlighting key corporate and clinical advancements across its vaccine and oncology programs. David Dodd, CEO of Geovax stated, “As highlighted in this report, during the third quarter GeoVax continued making important progress, advancing innovative vaccines and immunotherapies that address urgent and underserved medical needs. With continued global Mpox spread and constrained vaccine supply, our GEO-MVA program represents a U.S.-based, scalable, next-generation MVA platform. Our EMA and BARDA-aligned program position GeoVax to accelerate regulatory readiness and commercial entry. For our GEO-CM04S1 COVID-19 vaccine program, recent clinical presentations validate our belief that multi-antigen vaccines – expressing both spike and nucleocapsid – are essential for breadth and durability in vulnerable immunocompromised populations. In particular, the robust immune responses demonstrated in Chronic Lymphocytic Leukemia (CLL) patients represents a meaningful step forward in addressing the unmet needs of over 40 million immunocompromised Americans. In our Gedeptin(R) oncology program, the expansion into multiple solid tumor indications builds upon a growing recognition that tumor-targeted immune priming can dramatically improve checkpoint outcomes. We are executing a clear path to clinical and commercial value creation. GeoVax continues to execute with purpose and discipline. Our multi-antigen vaccine and immunotherapy platforms position the Company squarely within the national call to strengthen America’s health security, expand domestic manufacturing, and deliver equitable global solutions.”

Volato Group, Inc. (NYSE American: SOAR, $1.20, +.84%) and M2i Global, Inc. (MTWO, $.10, +5.26%) announced (Oct. 16) the next phase of development of the digital and commercial infrastructure underpinning the U.S. Strategic Mineral Reserve (SMR). M2i initiated the SMR framework and technical specifications earlier this year. Volato is now applying its proven enterprise-software expertise to build and operationalize the secure technology backbone that will support critical mineral traceability, contracting, and compliance across the United States and allied nations. This infrastructure is being developed to serve as the market-facing layer of the U.S. Strategic Mineral Reserve initiative, providing miners, refiners, recyclers, manufacturers, and government entities with a trusted environment for physical critical mineral transactions—with verified provenance, end-to-end custody visibility, and regulatory compliance at its core.

Serina Therapeutics (NYSE American: SER, $3.76) stands at a pivotal juncture as it harnesses fresh capital, regulatory momentum, and a sharpened communications strategy to propel its lead program, SER-252, into late-stage clinical testing for advanced Parkinson’s diseas. The Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies.

The InterGroup Corporation (NASDAQ: INTG, $34.72) reported results (Oct. 9) for the fiscal year ended June 30, 2025, including improved segment income in Hotel and Real Estate, increased liquidity, the alleviation of going-concern uncertainty at majority-owned subsidiary Portsmouth Square, Inc., and the Company’s return to compliance with Nasdaq listing requirements.

The Sources

by Vista Partners LLC November 18, 2025

Claude Shakes Up Cloud Wars: Anthropic’s Epic $30 Billion Microsoft Deal -( $MSFT $NVDA $DIA )

Anthropic, the AI shop best known for giving ChatGPT’s Claude a run for its money, has announced a jaw-dropping, spreadsheet-busting $30 billion commitment to Microsoft’s Azure cloud platform—a sum large enough to make even the most seasoned CFO reach for a calculator and a calming cup of chamomile tea. The deal, revealed Tuesday, places Anthropic squarely in the ringside seats of the generative AI arms race, and brings with it a rotating cast of tech titans and supersized investment numbers worthy of a Silicon Valley fever dream.

The Cast: Microsoft, Nvidia, and (Not) OpenAI

Anthropic’s latest strategic alliance partners read like an AI industry wish list. In addition to the astronomical Azure tab, Microsoft will invest up to $5 billion in Anthropic—a show of courtship not seen since the cloud giant’s still-simmering romance with OpenAI. Meanwhile, Nvidia has entered the fray with its own $10 billion investment, ensuring that any upgrades to Claude’s cerebral powers will run on nothing less than the chipmaker’s bleeding-edge silicon.

In a move sure to get cloud competitors nervously checking their uptime SLAs, Anthropic’s Claude models are set to be available across Microsoft Foundry, 365 Copilot, and Copilot Studio. This makes Claude the only so-called “frontier” AI model to appear on all three of the world’s major cloud platforms, a kind of cross-cloud omnipresence that would make even the most jaded cloud evangelist sit up straighter—if only to request more compute capacity.

The Funding Arms Race

Anthropic’s big bet comes shortly after a $13 billion Series F funding round led by Iconiq, which boosted its valuation to a stratospheric $183 billion. If that sounded impressive, consider that Microsoft’s tab for cloud compute ($30 billion and counting) is nearly equivalent to the GDP of a small country, or—more aptly—the lunchtime snack budget at a tech unicorn communal kitchen.

The company, whose customer base has multiplied nearly sevenfold in just a year, sits at the center of an AI investment binge that shows no signs of abating. For context, venture funding into AI startups hit $40 billion in one recent quarter, with foundation model providers like Anthropic raking in the lion’s share—the lion, the safari jeep, and half the savannah, to boot.

Cloud Drama and Backstage Intrigue

While Azure now has its hooks in Anthropic, Amazon remains the company’s primary training partner and cloud provider—for now. This tangled web of cloud relationships recalls the plot twists of a prestige streaming drama: just when you think you know which hyperscaler is in charge, another makes an entrance with a checkbook the size of a small aircraft carrier.

For Microsoft, the Anthropic partnership is a not-so-subtle signal that there’s room in its AI harem for more than just OpenAI. And for Nvidia, the deal cements its position as not just the engine room of AI, but also the financier—the Midas with motherboards.

Final Numbers—And a Dash of Perspective

Here’s the bottom line: Anthropic will buy up to one gigawatt of Azure compute for Claude’s growing talents, with Microsoft and Nvidia each betting heavily on Anthropic’s continued rise. Claude, for its part, is now poised to power everything from enterprise chatbots to Copilot integrations, ensuring that boardroom debates about “AI strategy” will be interrupted only by requests for more Claude credits—or the latest Nvidia GPU.

For now, the industry awaits the next act in this high-stakes AI pageant. Bring popcorn, and maybe a spare power cord. You’ll need both.

The Sources…

[1] Anthropic commits $30 billion to Microsoft Azure compute https://finance.yahoo.com/news/anthropic-commits-30-billion-microsoft-150718518.html
[2] Microsoft partners with Anthropic and Nvidia in cloud infrastructure deal https://uk.finance.yahoo.com/news/microsoft-partners-anthropic-nvidia-cloud-154827569.html
[3] Microsoft, NVIDIA and Anthropic forge major AI partnerships https://finance.yahoo.com/news/microsoft-nvidia-anthropic-forge-major-153634018.html
[4] Microsoft, NVIDIA and Anthropic announced new strategic partnerships. https://www.anthropic.com/news/microsoft-nvidia-anthropic-announce-strategic-partnerships
[5] Microsoft, NVIDIA and Anthropic announce strategic partnerships https://blogs.microsoft.com/blog/2025/11/18/microsoft-nvidia-and-anthropic-announce-strategic-partnerships/
[6] Nvidia, Microsoft Pour $15 Billion Into Anthropic for New AI Alliance https://www.wsj.com/tech/ai/nvidia-microsoft-and-anthropic-commit-to-roughly-45-billion-in-ai-partnership-281b7b1d
[7] Anthropic lands $15 billion investment from Microsoft, Nvidia https://www.axios.com/2025/11/18/anthropic-microsoft-nvidia-15-billion
[8] Anthropic valued in range of $350 billion following investment deal … https://www.cnbc.com/2025/11/18/anthropic-ai-azure-microsoft-nvidia.html
[9] Claude now available in Microsoft Foundry and Microsoft 365 Copilot https://www.anthropic.com/news/claude-in-microsoft-foundry
[10] Introducing Anthropic’s Claude models in Microsoft Foundry: Bringing Frontier intelligence to Azure https://azure.microsoft.com/en-us/blog/introducing-anthropics-claude-models-in-microsoft-foundry-bringing-frontier-intelligence-to-azure/
[11] Anthropic Raises Its Valuation to $183 Billion in New Funding https://www.nytimes.com/2025/09/02/technology/anthropic-funding-ai.html
[12] Anthropic Nearly Triples Valuation To $183B With Massive New … https://news.crunchbase.com/venture/generative-ai-anthropic-funding-iconiq/
[13] Anthropic raises $13B Series F at $183B post-money valuation https://www.anthropic.com/news/anthropic-raises-series-f-at-usd183b-post-money-valuation
[14] Microsoft’s new Anthropic partnership brings Claude AI models to Azure https://www.theverge.com/news/822988/microsoft-anthropic-partnership-claude-models-azure-investment-nvidia
[15] Microsoft, Nvidia to invest in Anthropic as Claude maker commits $30 billion to Azure https://finance.yahoo.com/news/anthropic-commits-30-billion-microsoft-150718625.html
[16] The latest circular AI deal stars Anthropic, Nvidia, and Microsoft https://www.aol.com/articles/latest-circular-ai-deal-stars-160506523.html
[17] Microsoft partners with Anthropic and Nvidia in cloud infrastructure … https://ca.finance.yahoo.com/news/microsoft-partners-anthropic-nvidia-cloud-152718628.html
[18] Microsoft, Nvidia team up with Anthropic in rare OpenAI-less deal https://finance.yahoo.com/video/microsoft-nvidia-team-anthropic-rare-160522302.html
[19] Microsoft partners with Anthropic and Nvidia in cloud infrastructure … https://finance.yahoo.com/news/microsoft-partners-anthropic-nvidia-cloud-152310008.html
[20] Microsoft, Nvidia to Invest a Combined $15 Billion in Anthropic https://finance.yahoo.com/video/microsoft-nvidia-invest-combined-15-154400665.html

by Vista Partners LLC November 18, 2025

Inside Ondas’ $225 Million Bet on Cyber Drone Takeover Technology with Sentrycs -( $ONDS $SPY )

Ondas Holdings (ONDS, $6.84, +166.80% YTD) has officially closed the $225 million deal to acquire Sentrycs, the Israeli cyber-wrangler with a knack for taking over rogue drones—no jamming, no spoofing, just pure protocol manipulation, much to the dismay of any quadcopter plotting against a G20 summit. In a move that’s part chess, part high-tech whack-a-mole, Ondas’ Autonomous Systems unit now absorbs Sentrycs’ vaunted Cyber-over-RF takeover platform, which boasts around 200 real-world deployments across 25 countries, from urban power grids to border outposts.

A Layered Defense for a Crowded Sky

The secret sauce? Layering. Ondas plans to blend Sentrycs’ cyber-takeover (think: digital drone puppeteering) with the Iron Drone Raider for physical intercepts, plus a generous dollop of AI for rapid decision-making. With the skies getting more congested than the L train on a Monday, this combined approach aims to keep everything from airport runways to critical infrastructure free of unauthorized UAV photobombers.

Market Momentum and Humor on the Balance Sheet

Ondas isn’t just talking a big game—they recently reported record quarterly revenue and a backlog so thick, it could serve as a decent doorstop for the CEO’s office. Executives say the Sentrycs acquisition arms them for a surge in defense and security contracts, pointing out that “mission-proven and operationally validated” counter-drone tech is less trend and more necessity in today’s world—though they’ve stopped short of promising to rid the world of all amateur drone light shows.

Integration Challenges and the Inevitable Fine Print

Skeptics may raise an eyebrow at the technical and operational lift required to fully integrate Sentrycs’ sci-fi takeover with Ondas’ existing arsenal. Customer procurement cycles are notoriously slow; don’t expect every airport to immediately swap out their air traffic controllers for an AI wielding a cyber-lasso.

For now, the message to Wall Street—and would-be drone interlopers—is clear: Ondas is betting the future of crowded airspace on a cocktail of Israeli code, Boston bravado, and more sensors than a NASA control room. As always, success, much like a drone interception, will come down to split-second execution—and, ideally, fewer drones straying off-script.

The Corporate Chess Match

Diagnosing Growth: Financials and Foresight

Strategic Humor and Market Satire

Sector Implications: A New Growth Engine

The Sum…

The Sources

A Retail Giant’s Holiday Playbook

E-Commerce: The New Engine of Growth

Wall Street’s Holiday Cheer

The Nasdaq Gambit

The Takeaway

The Sources…

S&P 500’s Nuclear Glow

Three Mile Island Reimagined

Enter Oklo: The DARPA of Nuclear?

Data Centers and the Aurora Order Book

The Nuclear Renaissance: High Stakes, High Humor

The Sources…

Insulet: podium position in patch pumps

Omnipod 5: the high‑end benchmark

Modular’s Pivot: the budget disruptor

Two patch pumps, one crowded lane

Investor angle: incumbents vs insurgents

The Sources..

Indices and macro backdrop

Rates, curve, tariffs and DC

Nvidia and the tech complex

Individual movers

Deals, IPOs, commodities and crypto

VP Watchlist Updates

The Sources

Big profit promises, modest patience

Two segments, one makeover

Chasing the AI supercycle

Margins, KPIs and a skeptical Street

From networks to narrative

The Sources…

A Clean Loop

Practical & Urgent

The Sum..

Further Afield: Volato and M2i Global Advance Development of Strategic Mineral Reserve Digital Infrastructure

Index Highlights

Macroeconomic Reports

Policy & Political Drama

Rates, Yield Curve, and Inflation

A Few Corporate updates

Commodities & Crypto

Today’s Market in One Line

VP Watchlist Updates

The Sources

The Cast: Microsoft, Nvidia, and (Not) OpenAI

The Funding Arms Race

Cloud Drama and Backstage Intrigue

Final Numbers—And a Dash of Perspective

The Sources…

A Layered Defense for a Crowded Sky

Market Momentum and Humor on the Balance Sheet

Integration Challenges and the Inevitable Fine Print

The Sources..

Your Guide To Staying Informed In The Markets